CA2380333A1 - Compositions pharmaceutiques - Google Patents
Compositions pharmaceutiques Download PDFInfo
- Publication number
- CA2380333A1 CA2380333A1 CA002380333A CA2380333A CA2380333A1 CA 2380333 A1 CA2380333 A1 CA 2380333A1 CA 002380333 A CA002380333 A CA 002380333A CA 2380333 A CA2380333 A CA 2380333A CA 2380333 A1 CA2380333 A1 CA 2380333A1
- Authority
- CA
- Canada
- Prior art keywords
- dosage form
- release
- active agent
- form according
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention se rapporte à de nouvelles compositions pharmaceutiques conçues pour retarder la libération d'un agent pharmaceutiquement actif. Une formulation médicamenteuse à libération retardée encapsule l'ingrédient actif, qui peut être appliqué sur des microparticules ou se présenter sous forme de comprimés, dans un enrobage retardateur de libération comportant des matières polymères dotées de caractéristiques préétablies de gonflement/perméabilité. Il est en particulier possible d'utiliser des mélanges de polymère d'acide acrylique et/ou d'acrylate, modifiés par des groupes ioniques. Dans une réalisation préférée, un polymère ayant une perméabilité dépendante du pH est utilisé en tant qu'élément plus perméable de l'enrobage. Ces formulations à libération retardée sont administrées sous une seule forme posologique, conjointement à des formulations à libération instantanée ou à libération retenue, de sorte qu'une forme posologique unique, de préférence une forme posologique orale, peut efficacement délivrer deux doses à un patient à des instants différents.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15088099P | 1999-08-26 | 1999-08-26 | |
US15089199P | 1999-08-26 | 1999-08-26 | |
US60/150,880 | 1999-08-26 | ||
US60/150,891 | 1999-08-26 | ||
US60/151,211 | 1999-08-26 | ||
US15121199P | 1999-08-27 | 1999-08-27 | |
PCT/GB2000/003309 WO2001013898A2 (fr) | 1999-08-26 | 2000-08-29 | Compositions pharmaceutiques |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2380333A1 true CA2380333A1 (fr) | 2001-03-01 |
Family
ID=27387049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002380333A Abandoned CA2380333A1 (fr) | 1999-08-26 | 2000-08-29 | Compositions pharmaceutiques |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1206250A2 (fr) |
AU (1) | AU6715600A (fr) |
CA (1) | CA2380333A1 (fr) |
WO (1) | WO2001013898A2 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
US6663888B2 (en) | 2001-12-14 | 2003-12-16 | Eurand Pharmaceuticals Ltd. | Pulsatile release histamine H2 antagonist dosage form |
WO2004034959A2 (fr) * | 2002-09-18 | 2004-04-29 | Elan Corporation, Plc | Preparation pharmaceutique |
MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
MXPA05004422A (es) * | 2002-10-25 | 2007-11-22 | Collegium Pharmaceutical Inc | Composiciones de milnacipran de liberacion pulsatil. |
US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
ES2241478B1 (es) * | 2004-02-13 | 2006-11-16 | Lacer S.A. | Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo. |
US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
CA2584957C (fr) | 2004-10-21 | 2015-08-25 | Eurand Pharmaceuticals Limited | Compositions pharmaceutiques a saveur masquee avec substances porogenes gastrosolubles |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
US8865197B2 (en) | 2005-09-06 | 2014-10-21 | Israel Oceanographic And Limnological Research Ltd. | Food formulation for aquatic animals with integrated targeted delivery of bioactive agents |
TW200711823A (en) * | 2005-09-30 | 2007-04-01 | Primax Electronics Ltd | Laminating device and laminating method for use in same |
WO2011067667A2 (fr) | 2009-12-02 | 2011-06-09 | Eurand Pharmaceuticals Limited | Microcapsules de fexofénadine et compositions les contenant |
KR101990951B1 (ko) * | 2015-04-27 | 2019-06-20 | 주식회사 네비팜 | 리바스티그민 함유 서방출 의약조성물 |
CN114159391B (zh) * | 2021-12-10 | 2023-05-05 | 卓和药业集团股份有限公司 | 重酒石酸卡巴拉汀干混悬剂及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5158777A (en) * | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
US5286497A (en) * | 1991-05-20 | 1994-02-15 | Carderm Capital L.P. | Diltiazem formulation |
US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
IL141762A0 (en) * | 1998-10-01 | 2002-03-10 | Novartis Ag | New oral formulations |
-
2000
- 2000-08-29 WO PCT/GB2000/003309 patent/WO2001013898A2/fr not_active Application Discontinuation
- 2000-08-29 AU AU67156/00A patent/AU6715600A/en not_active Abandoned
- 2000-08-29 EP EP00954802A patent/EP1206250A2/fr not_active Withdrawn
- 2000-08-29 CA CA002380333A patent/CA2380333A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU6715600A (en) | 2001-03-19 |
WO2001013898A3 (fr) | 2001-05-25 |
EP1206250A2 (fr) | 2002-05-22 |
WO2001013898A2 (fr) | 2001-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7781448B2 (en) | Once daily dosage forms of trospium | |
EP2265261B1 (fr) | Systèmes d'administration de médicaments comprenant des médicaments faiblement basiques et des acides organiques | |
CA2380333A1 (fr) | Compositions pharmaceutiques | |
US20030157169A1 (en) | Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile monohydrochloride | |
EP0929301A2 (fr) | Formulation a liberation lente de monohydrochlorure de r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo 2.2.2]oct-3-yl)acetonitrile | |
JP2003507416A (ja) | 医薬製剤 | |
US20040228918A1 (en) | Granule modulating hydrogel system | |
MXPA06004017A (es) | Formas de dosis una vez al dia de trospio |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |